Abstract Library

#4544 Spatial and temporal intratumour heterogeneity of pancreatic neuroendocrine tumours (PanNET)

Introduction: Data derived from the study of intertumour heterogeneity have led to propose that PanNET evolution may start either from beta cells with good prognosis, or from alpha cells with sequential alterations of MDA (MENIN-DAXX/ATRX) leading to more aggressive lesions.

Conference:

Presenting Author: Awan Z

Authors: Awan Z, Bourdeleau P, Epée J, Ps H, Tihy M,

Keywords: Pancreatic neuroendocrine tumour, Heterogeneity, Tumour microenvironment,

#4455 Multicentric ENETS morphological and molecular appraisal of high-grade gastroenteropancreatic neuroendocrine neoplasms (HG-GEP-NEN): Distinguishing NET G3 from NEC

Introduction: HG-GEP-NEN are classified into neuroendocrine tumours grade 3 (NET G3) and neuroendocrine carcinomas (NEC). This distinction is crucial as it affects patient prognosis and treatments but can be challenging.

Conference:

Presenting Author: Tihy M

Authors: Tihy M, Solstad O, Oudijk L, Bräutigam K, Bani M,

Keywords: HG-GEP-NEN, neuroendocrine neoplasm, NEC, NET G3, Classification, Review, criteria, diagnosis, pathology,

#4454 Impact of pathological review of neuroendocrine neoplasms (NENs) within the French national ENDOCAN/TENpath network

Introduction: NENs are rare tumours which can benefit from specialised pathological assessment. In France, the ENDOCAN/TENpath network, composed of 33 expert pathologists in 20 centres, provides consultations (2nd readings) at the request of non-specialist pathologists. Challenging cases are reviewed in monthly virtual meetings grouping all expert pathologists (third readings).

Conference:

Presenting Author: Tihy M

Authors: Tihy M, Scoazec J, Bani M, Boulagnon-Rombi C, Poté N,

Keywords: NEN, Pathology, Review, Neuroendocrine Neoplasm,

#3848 LITESPARK-015 cohort B1 – A phase 2 open-label study of Belzutifan (a HIF-2α inhibitor) monotherapy in patients with von Hippel-Lindau (VHL) disease–associated tumors

Introduction: Patients (pts) with von Hippel-Lindau (VHL) disease need novel targeted therapies. Hypoxia-inducible factor 2α (HIF-2α) is a key oncogenic driver in VHL disease. Belzutifan (MK-6482), a HIF-2α inhibitor, has shown antitumor activity in pts with advanced renal cell carcinoma (RCC) and pancreatic neuroendocrine tumors (pNETs); more data are needed in VHL disease–associated localized tumors.

Conference:

Presenting Author:

Authors: Walter T, Gong K, Nakamura E, Iliopoulos O, Jimenez C,

Keywords: von Hippel-Lindau disease, belzutifan, MK-6482,

#2905 DNA Methyltransferase Inhibitor Hydralazine Induces Upregulation of Somatostatin Type 2 Receptors in Human Neuroendocrine Tumor Cells

Introduction: Epidrugs like DNA methyltransferase inhibitors (DNMTi) can increase somatostatin receptor type 2 (SST2) expression in neuroendocrine tumor (NET) cells in vitro and in vivo. This effect could be used for NET patients with low SST2 expression who are currently ineligible for somatostatin analogue (SSA) treatment. However, the DNMTi known to stimulate SST2 have either a high toxicity profile or are not yet approved.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Refardt J

Authors: Refardt J, Klomp I, van Koetsveld P, Dogan-Oruç F, de Herder W,

Keywords: somatostatin type 2 receptor, BON-1, GOT-1, upregulation, DNA methyltransferase inhibitor, histone deacetylase inhibitor, epigenetic,